Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study
Alice Chen,Geraldine O’Sullivan Coyne,Pamela L. Wolters,Staci Martin,Said Farschtschi,Ignacio Blanco,Zhongping Chen,Luiz Guilherme Darrigo,Marica Eoli,James R. Whittle,Yoshihiro Nishida,Rosa Lamarca,Randolph de la Rosa Rodríguez,Ayoade Adeyemi,I. Herrero,Nereida Llorente,Scott J. Diede,Eva Dombi,P. Wolkenstein,Alexander T.J. Lee